Metformin in the first trimester and risks for specific birth defects in the National Birth Defects Prevention Study

Stephanie Dukhovny, Carla M. Van Bennekom, David R. Gagnon, Sonia Hernandez Diaz, Samantha E. Parker, Marlene Anderka, Martha M. Werler, Allen A. Mitchell

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: We assessed associations between first-trimester metformin use for pregestational diabetes and specific major birth defects. Methods: We compared risks associated with first-trimester metformin use by diabetic women to nondiabetic women on no diabetes medication; we calculated crude odds ratios by exact logistic regression and adjusted by inverse probability weighting. Confounding by diabetes was assessed by comparing risks for metformin-exposed diabetic women to those for insulin-exposed diabetics and nondiabetics treated with metformin for subfertililty. Results: Among 9,279 nonmalformed controls and 24,375 malformed cases, diabetics who used metformin (with or without insulin) had increased adjusted odds ratios (aORs) for several birth defects associated with diabetes. However, women treated with metformin for subfertility had aORs similar to or lower than those for diabetic metformin users, and many approximated the null. For atrial septal defect secundum, anorectal defects, and limb reduction defects, the estimates for metformin when used for subfertility were 2–3-fold. Conclusion: While metformin use for diabetes was associated with an increased risk of many birth defects, when metformin was used for subfertility most defects had aORs that approximated the null, while only three defects had modestly increased aORs, two of which had lower confidence bounds that included the null. Our study does not suggest that metformin poses an appreciable risk for major birth defects, but further studies are necessary.

Original languageEnglish (US)
Pages (from-to)579-586
Number of pages8
JournalBirth Defects Research
Volume110
Issue number7
DOIs
StatePublished - Apr 17 2018

Fingerprint

Metformin
First Pregnancy Trimester
Defects
Medical problems
Odds Ratio
Infertility
Insulin
Atrial Heart Septal Defects
Logistics
Extremities
Logistic Models

Keywords

  • birth defects
  • diabetes
  • metformin
  • National Birth Defects Prevention Study
  • oral hypoglycemic agents
  • polycystic ovarian syndrome

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Embryology
  • Toxicology
  • Developmental Biology
  • Health, Toxicology and Mutagenesis

Cite this

Dukhovny, S., Van Bennekom, C. M., Gagnon, D. R., Hernandez Diaz, S., Parker, S. E., Anderka, M., ... Mitchell, A. A. (2018). Metformin in the first trimester and risks for specific birth defects in the National Birth Defects Prevention Study. Birth Defects Research, 110(7), 579-586. https://doi.org/10.1002/bdr2.1199

Metformin in the first trimester and risks for specific birth defects in the National Birth Defects Prevention Study. / Dukhovny, Stephanie; Van Bennekom, Carla M.; Gagnon, David R.; Hernandez Diaz, Sonia; Parker, Samantha E.; Anderka, Marlene; Werler, Martha M.; Mitchell, Allen A.

In: Birth Defects Research, Vol. 110, No. 7, 17.04.2018, p. 579-586.

Research output: Contribution to journalArticle

Dukhovny, S, Van Bennekom, CM, Gagnon, DR, Hernandez Diaz, S, Parker, SE, Anderka, M, Werler, MM & Mitchell, AA 2018, 'Metformin in the first trimester and risks for specific birth defects in the National Birth Defects Prevention Study', Birth Defects Research, vol. 110, no. 7, pp. 579-586. https://doi.org/10.1002/bdr2.1199
Dukhovny, Stephanie ; Van Bennekom, Carla M. ; Gagnon, David R. ; Hernandez Diaz, Sonia ; Parker, Samantha E. ; Anderka, Marlene ; Werler, Martha M. ; Mitchell, Allen A. / Metformin in the first trimester and risks for specific birth defects in the National Birth Defects Prevention Study. In: Birth Defects Research. 2018 ; Vol. 110, No. 7. pp. 579-586.
@article{215826c84b1f4743bb41550be65187d9,
title = "Metformin in the first trimester and risks for specific birth defects in the National Birth Defects Prevention Study",
abstract = "Background: We assessed associations between first-trimester metformin use for pregestational diabetes and specific major birth defects. Methods: We compared risks associated with first-trimester metformin use by diabetic women to nondiabetic women on no diabetes medication; we calculated crude odds ratios by exact logistic regression and adjusted by inverse probability weighting. Confounding by diabetes was assessed by comparing risks for metformin-exposed diabetic women to those for insulin-exposed diabetics and nondiabetics treated with metformin for subfertililty. Results: Among 9,279 nonmalformed controls and 24,375 malformed cases, diabetics who used metformin (with or without insulin) had increased adjusted odds ratios (aORs) for several birth defects associated with diabetes. However, women treated with metformin for subfertility had aORs similar to or lower than those for diabetic metformin users, and many approximated the null. For atrial septal defect secundum, anorectal defects, and limb reduction defects, the estimates for metformin when used for subfertility were 2–3-fold. Conclusion: While metformin use for diabetes was associated with an increased risk of many birth defects, when metformin was used for subfertility most defects had aORs that approximated the null, while only three defects had modestly increased aORs, two of which had lower confidence bounds that included the null. Our study does not suggest that metformin poses an appreciable risk for major birth defects, but further studies are necessary.",
keywords = "birth defects, diabetes, metformin, National Birth Defects Prevention Study, oral hypoglycemic agents, polycystic ovarian syndrome",
author = "Stephanie Dukhovny and {Van Bennekom}, {Carla M.} and Gagnon, {David R.} and {Hernandez Diaz}, Sonia and Parker, {Samantha E.} and Marlene Anderka and Werler, {Martha M.} and Mitchell, {Allen A.}",
year = "2018",
month = "4",
day = "17",
doi = "10.1002/bdr2.1199",
language = "English (US)",
volume = "110",
pages = "579--586",
journal = "Birth Defects Research",
issn = "2472-1727",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Metformin in the first trimester and risks for specific birth defects in the National Birth Defects Prevention Study

AU - Dukhovny, Stephanie

AU - Van Bennekom, Carla M.

AU - Gagnon, David R.

AU - Hernandez Diaz, Sonia

AU - Parker, Samantha E.

AU - Anderka, Marlene

AU - Werler, Martha M.

AU - Mitchell, Allen A.

PY - 2018/4/17

Y1 - 2018/4/17

N2 - Background: We assessed associations between first-trimester metformin use for pregestational diabetes and specific major birth defects. Methods: We compared risks associated with first-trimester metformin use by diabetic women to nondiabetic women on no diabetes medication; we calculated crude odds ratios by exact logistic regression and adjusted by inverse probability weighting. Confounding by diabetes was assessed by comparing risks for metformin-exposed diabetic women to those for insulin-exposed diabetics and nondiabetics treated with metformin for subfertililty. Results: Among 9,279 nonmalformed controls and 24,375 malformed cases, diabetics who used metformin (with or without insulin) had increased adjusted odds ratios (aORs) for several birth defects associated with diabetes. However, women treated with metformin for subfertility had aORs similar to or lower than those for diabetic metformin users, and many approximated the null. For atrial septal defect secundum, anorectal defects, and limb reduction defects, the estimates for metformin when used for subfertility were 2–3-fold. Conclusion: While metformin use for diabetes was associated with an increased risk of many birth defects, when metformin was used for subfertility most defects had aORs that approximated the null, while only three defects had modestly increased aORs, two of which had lower confidence bounds that included the null. Our study does not suggest that metformin poses an appreciable risk for major birth defects, but further studies are necessary.

AB - Background: We assessed associations between first-trimester metformin use for pregestational diabetes and specific major birth defects. Methods: We compared risks associated with first-trimester metformin use by diabetic women to nondiabetic women on no diabetes medication; we calculated crude odds ratios by exact logistic regression and adjusted by inverse probability weighting. Confounding by diabetes was assessed by comparing risks for metformin-exposed diabetic women to those for insulin-exposed diabetics and nondiabetics treated with metformin for subfertililty. Results: Among 9,279 nonmalformed controls and 24,375 malformed cases, diabetics who used metformin (with or without insulin) had increased adjusted odds ratios (aORs) for several birth defects associated with diabetes. However, women treated with metformin for subfertility had aORs similar to or lower than those for diabetic metformin users, and many approximated the null. For atrial septal defect secundum, anorectal defects, and limb reduction defects, the estimates for metformin when used for subfertility were 2–3-fold. Conclusion: While metformin use for diabetes was associated with an increased risk of many birth defects, when metformin was used for subfertility most defects had aORs that approximated the null, while only three defects had modestly increased aORs, two of which had lower confidence bounds that included the null. Our study does not suggest that metformin poses an appreciable risk for major birth defects, but further studies are necessary.

KW - birth defects

KW - diabetes

KW - metformin

KW - National Birth Defects Prevention Study

KW - oral hypoglycemic agents

KW - polycystic ovarian syndrome

UR - http://www.scopus.com/inward/record.url?scp=85045687674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045687674&partnerID=8YFLogxK

U2 - 10.1002/bdr2.1199

DO - 10.1002/bdr2.1199

M3 - Article

C2 - 29388358

AN - SCOPUS:85045687674

VL - 110

SP - 579

EP - 586

JO - Birth Defects Research

JF - Birth Defects Research

SN - 2472-1727

IS - 7

ER -